How critical is intellectual property

 to a biotech startup?

 

Targets - are they worthwhile patenting, and, if so, when?

Can we claim any drug that hits a certain enzyme's active site?

Should we file as early as possible, or wait for more data?

Should we include every possible functional group on a given basic structure?

Provisional patent applications - are they worthwhile? What is the best way to use them?

How can we have our patent issue as soon as possible?

Should we file overseas, and if so, where?

How can we maximize coverage while holding costs down?

What is the best way to work with our scientific advisory board?

                                                                               

Questions such as these arise in every biotech startup, but objective answers are often difficult to come by.

Intellectual property – the value driver for startups

For most biotech startups their product – and typically their only asset – is their IP, or intellectual property. Because the scope and strength of their patent portfolio will determine their ability to attract investors and strategic partners – and ultimately to succeed – the fate of biotech startups depends critically upon their intellectual property.

 

Patenting Strategy, LLC, a consultancy based in Carlsbad, CA, provides the consulting services of Stephen R. Cooper, Ph.D., an experienced registered patent agent and researcher (former faculty member in chemistry at Harvard and Oxford, with extensive pharma and biotech startup experience) to help with these and the other patent strategy questions that vex biotech managers and investors. We work with startups to generate and protect rock-solid, broad IP, thereby building value in the company - all in a financially-flexible and cost-effective fashion.